Paraneoplastic cerebellar degeneration associated with small cell neuroendocrine mediastinal carcinoma

Degeneración cerebelosa paraneoplásica asociada a carcinoma neuroendocrino mediastínico de células pequeñas

To the Editor,

We report the case of a 69-year-old woman admitted with a 7-month history of anorexia and asthenia, along with unsteadiness, vomiting, tremor and double vision. She also reported a 1-month history of dyspnea and voice changes. On examination, she presented a bilateral voice, ataxic gait and dysmetria, with intention tremor in the left arm. Magnetic resonance imaging (MRI) of the head revealed a small lacunar infarction, which did not explain the clinical symptoms. Blood work, biochemistry, proteins, immunoglobulins, thyroid profile, vitamin B₁₂, vitamin E and folate were normal, and serologies for HIV, hepatitis, cytomegalovirus, Epstein–Barr virus, syphilis and Borrelia were all negative. Cerebrospinal fluid cytology was also normal. Carcinomembronic antigen and neurospecific enolase tumor markers were elevated at 30.4 ng/ml (0–5 ng/ml) and 21.7 ng/ml (0–16 ng/ml), respectively. A computed tomography (CT) of the chest and abdomen revealed a mass in the upper mediastinum, measuring 70 mm × 40 mm, suggestive of clustered lymphadenopathy. An immune-mediated process was suspected, so antinuclear antibodies and onconeural antibodies were tested, but these were negative, with anti-glutamic acid decarboxylase antibodies (anti-GAD) 2.4 U/ml (0–5 U/ml) and anti-acetylcholine receptor antibodies 0.01 nmol/l (0–0.1 nmol/l). F-18 fluorodeoxyglucose uptake on a positron emission tomography scan suggested malignancy, so a biopsy was obtained by mediastinoscopy. The pathology report confirmed small cell neuroendocrine carcinoma of the thymus, positive for chromogranin and synaptophysin. A histology slide of the thymus scan showed malignancy. The patient underwent surgical resection and received chemotherapy with carboplatin and etoposide. She achieved full remission of the cancer and almost complete resolution of her neurological symptoms, although tremor at rest did persist.

Neuroendocrine tumors (NET) are rare cancers, generally found in the gastrointestinal tract, although they may occur in the lung, thymus, ovaries and non-parenchymatous tissue. Thymic NETs account for less than 5% of mediastinal tumors. Approximately 30% are malignant, although this rate rises to 82% if they are located in the thymus. They present as a mediastinal mass mainly in patients aged 30–50 years, and are 3 times more common in men. Local clinical manifestations can range from dysphonia or dyspnea to superior vena cava syndrome, and one-third of patients have endocrine symptoms associated with multiple endocrine neoplasia syndrome. CT, MRI and 18F-fluorodeoxyglucose PET scanning are helpful, but the octreoscan is the most sensitive procedure (71%–100%) for detecting NETs, depending on the somatostatin receptors expressed by the tumors. Histology examination shows cell nests with fibrovascular tracts, positive for neuroendocrine markers such as chromogranin, synaptophysin and neuroendolase. Paraneoplastic cerebellar degeneration (PCD) is the most common paraneoplastic neurological syndrome. In 18%–50% of cases, no antibodies are identified, and in early stages of the disease, MRI is normal. It is associated with several neoplastic processes, including thymic NETs.

In view of the favorable response to specific cancer treatment, we classified our case as seronegative PCD associated with thymic NET.

References

Cortico-dependent Asthma: Our Clinical Experience

Asma corticodependiente: nuestra experiencia clínica

To the Editor,

Corticosteroid-dependent asthma is defined as the need for daily administration of oral corticosteroids. This definition, however, is ambiguous, since it includes both patients who receive this treatment and experience little improvement, and those who benefit from it (with a varying degree of response). The GOAL study showed that only 7% of patients who were uncontrolled at maximum doses of fluticasone/salmeterol achieved control with an oral steroid regimen. Few studies have been conducted in this specific patient group, despite their clinical relevance. We report the case of a patient with corticosteroid-dependent asthma, and review the management and progress of all corticosteroid-dependent asthmatics seen in our specialist clinic (10 of a total of 475 patients).

A 69-year-old woman, non-smoker, with a diagnosis of late-onset, non-allergic asthma, IgE 770 kU/l, eosinophils 900/mm³, FENO 31 ppb. Asthma was initially poorly controlled with a combination of maximum doses of budesonide/formoterol, as indicated by asthma control test (ACT) 15, a severe exacerbation in the previous year, FEV₁ 64%, and positive bronchodilator challenge. Significant comorbidities included rhinosinusitis and obesity. Treatment with deflazacort 30 mg for 3 weeks increased ACT to 23 and FEV₁ to 67%, but when it was withdrawn, ACT returned to 16 and FEV₁ to 67%. Tiotropium (18 μg/day) was added to the combination of fluticasone/salmeterol (500/50 μg), but ACT remained unchanged, while FEV₁ rose to 70%. Treatment was subsequently switched to inhaled fluticasone (1000 μg/day), tiotropium (18 μg/day) and indacaterol (150 μg/day). The patient is currently free of exacerbations, her ACT is 24 and FEV₁ is 79%.

In our opinion, a patient who is uncontrolled and presents bronchial obstruction despite treatment with a combination of maximum dose inhaled corticosteroids (IC)-long-acting β-2 agonist (LABA) has corticosteroid-dependent asthma. In the case of our patient, her FEV₁ normalized (at least to >70%) and ACT rose to ≥20 after 3–4 weeks of treatment with deflazacort 30 mg. Subsequently, when the oral corticosteroid was discontinued, her clinical and functional status returned to the previous situation.

Clinical characteristics, treatment, and progress of patients with corticosteroid-dependent asthma

Ten of our patients (of 475 regularly seen in our consulting rooms) had corticosteroid-dependent asthma. They were typically middle-aged (49.2±15.1 years), with late onset of symptoms (7/10 cases), intense peripheral eosinophilia (eosinophils 565.0±286.8/mm³), elevated IgE (379.7±357.3 kU/l), FENO (31.7±13.2 ppb), and significant comorbidities (particularly obesity, rhinosinusitis, and polyposis). Despite the correct use of IC/LABA at maximum doses, these patients remained symptomatic with signs of bronchial obstruction, yet only 2 developed 2 or more severe exacerbations in a period of 1 year. It seems that in most cases, standard treatment can prevent exacerbations, while failing to provide full control of symptoms or normalization of lung function. This was achieved in all cases when an oral corticosteroid was added, although this treatment was unacceptable due to adverse events.

These 10 patients were managed by the same pulmonologist. For the 2 patients in whom severe exacerbations persisted, the treatment strategy consisted, firstly, of adding omalizumab to the regimen. The response of the patients who received omalizumab confirmed its efficacy in reducing exacerbations, but also its lack of effect on lung function. Persisting bronchial obstruction may explain why optimal control of symptoms is elusive in many patients.

The next step for all patients consisted of adding a long-acting muscarinic antagonist, a medication that has already demonstrated its efficacy in this clinical setting. This intervention helped improve patients’ lung function and symptoms, but to an insufficient degree in 7 cases. We decided to add indacaterol to these 7 patients’ regimens: this potent bronchodilator has demonstrated efficacy in chronic obstructive pulmonary disease, but little experience is available in asthma. This combined therapeutic strategy resulted in a significant improvement in lung function and symptoms (Table 1) among corticosteroid-dependent asthma patients, while avoiding the use of oral steroids.

**Table 1**

<table>
<thead>
<tr>
<th></th>
<th>Initial</th>
<th>Final</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACT</td>
<td>16.9±3.8</td>
<td>22.5±2.7</td>
</tr>
<tr>
<td>Exacerbations/patient/year</td>
<td>0.32</td>
<td>0</td>
</tr>
<tr>
<td>FEV₁%</td>
<td>53.5±14.2</td>
<td>76.4±13.3</td>
</tr>
<tr>
<td>Oral corticosteroids</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Omalizumab</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>LAMA</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td>Indacaterol</td>
<td>0</td>
<td>7</td>
</tr>
</tbody>
</table>

ACT: asthma control tests; FEV₁%: forced expiratory volume in 1 second; LAMA: long-acting anticholinergics.

**Conflict of Interests**

Dr Pérez de Llano has received payment from Novartis, Boehringer, Chiesi, Almirall, Esteve and Ferrer, for presentations at medical congresses, consultancy, and coordination or participation in medical advisory boards. He has received honoraria from Novartis, Boehringer, Chiesi, Almirall, Esteve and Ferrer, for presentations at medical congresses, consultancy, and coordination or participation in medical advisory boards. He has received honoraria from Novartis and Boehringer, for presentations at medical congresses, consultancy, and coordination or participation in medical advisory boards.

**Authorship**

Study concept and design, data collection, analysis of results, interpretation of findings, and drafting the manuscript: Pérez de Llano.

Study design and data collection: García Rivero and Pallares.

Data collection: Mengual.

Data analysis and interpretation of results: Golpe.


José Luis Serrano-Martínez, a, b Mónica Zamora-Pasadas, a María Redondo-Orts a

a Servicio de Medicina Interna, Hospital Universitario Virgen de las Nieves, Granada, Spain

b Servicio de Cuidados Críticos y Urgencias, Hospital Universitario Virgen de las Nieves, Granada, Spain

corresponding author.

E-mail address: jlserranomi@gmail.com (J.L. Serrano-Martínez).